| 2024-04 |
Clinical Activity of TGF-β Inhibitor Vactosertib in Combination with Imatinib in Desmoid Tumors: A Multicenter Phase Ib/II Study |
Clinical Cancer Research
|
| 2024-01 |
Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial |
Nature Communications
|
| 2024-01 |
Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial |
Nature Communications
|
| 2023-09 |
Sustained deep partial response with axitinib and pembrolizumab in a patient with alveolar soft-part sarcoma: A case report and review of the literature |
PEDIATRIC BLOOD & CANCER
|
| 2023-04 |
Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response |
Cancer Research and Treatment
|
| 2022-12 |
Therapeutic Implications of TGF-beta Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties |
CANCERS
|
| 2022-10 |
Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study |
Cancer Research and Treatment
|
| 2022-08 |
Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma |
CLINICAL CANCER RESEARCH
|
| 2021-03 |
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma |
BMC CANCER
|
| 2021-03 |
Prognostic implications of PD-L1 expression in patients with angiosarcoma |
Future Science OA
|
| 2020-09 |
Comprehensive immuno-molecular profiles for liposarcoma: Roles of programmed death ligand 1, microsatellite instability, and pik3ca |
ONCOLOGY
|
| 2019-02 |
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. |
ONCOLOGY
|